STAT3 and Familial prostate cancer: In another study, STAT3 small interfering (si)RNA conjugated to cpG oligonucleotide agonist of TLR9 targeted tumor associated myeloid cells by silencing STAT3, thus leading to a potent antitumor immune response in multiple tumor mouse models (Kortylewski et al., 2009) and prostate cancer patients (Hossain et al., 2015).